Global Overactive Bladder Treatment Market to Exhibit Substantial Growth at a CAGR of ~4% by 2032 | DelveInsight
The overactive bladder treatment market is experiencing steady growth driven by the increasing prevalence of OAB, especially among the aging population. Rising awareness about urinary disorders and the availability of new pharmacological therapies, including antimuscarinics and β3-adrenergic agonists, are expanding treatment adoption. Additionally, the development of minimally invasive procedures and combination therapies is enhancing patient outcomes, further fueling the overactive bladder treatment market demand.
New York, USA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Global Overactive Bladder Treatment Market to Exhibit Substantial Growth at a CAGR of ~4% by 2032 | DelveInsight
The overactive bladder treatment market is experiencing steady growth driven by the increasing prevalence of OAB, especially among the aging population. Rising awareness about urinary disorders and the availability of new pharmacological therapies, including antimuscarinics and β3-adrenergic agonists, are expanding treatment adoption. Additionally, the development of minimally invasive procedures and combination therapies is enhancing patient outcomes, further fueling the overactive bladder treatment market demand.
DelveInsight’s Overactive Bladder Treatment Market Insights report provides the current and forecast market analysis, individual leading overactive bladder treatment companies’ market shares, challenges, overactive bladder treatment market drivers, barriers, trends, and key market overactive bladder treatment companies in the market.
Overactive Bladder Treatment Market Summary
- The global overactive bladder treatment market size is projected to increase from USD 3.8 billion in 2024 to USD 5.1 billion by 2032, reflecting strong and sustained growth.
- The global overactive bladder treatment market is expected to grow at a CAGR of ~4% during the forecast period from 2025 to 2032.
- The leading companies working in the overactive bladder treatment market include Pfizer Inc., Astellas Pharma Inc., Amneal Pharmaceuticals LLC, Sumitomo Pharma Co., Ltd., Novartis AG, Endo, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Hisamitsu Pharmaceutical Co., Inc., Viatris Inc., Medtronic, Axonics, Inc., Valencia Technologies, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Zydus Group, DAIICHI SANKYO COMPANY, LIMITED, KYORIN Pharmaceutical Co., Ltd., Neuspera Medical, and others.
- Among all the regions, North America is anticipated to register the fastest growth in the overactive bladder treatment market during the forecast period.
- In the treatment type segment of the overactive bladder treatment market, the anticholinergic drugs category accounted for the largest market share in 2024.
To read more about the latest highlights related to the overactive bladder treatment market, get a snapshot of the key highlights entailed in the Global Overactive Bladder Treatment Market Forecast Report
Key Factors Contributing to the Rise in Growth of the Overactive Bladder Treatment Market
Rising Prevalence of Overactive Bladder
The incidence of OAB is steadily increasing, particularly in aging populations. Age-related bladder changes, combined with the growing burden of diabetes and obesity, are expanding the patient pool in need of effective therapies.
Advancements in Pharmacological Therapies
Novel drug classes such as antimuscarinics, β3-adrenergic agonists, and combination regimens are broadening treatment choices. With improved efficacy, safety, and tolerability, these therapies are gaining wider acceptance among physicians and patients.
Impact of Comorbid Conditions
Neurological disorders, bladder and prostate cancers, and urinary tract infections often aggravate OAB symptoms, creating additional demand for targeted treatment approaches within broader disease management frameworks.
Technological Innovations in Device-Based Therapies
Minimally invasive solutions like neuromodulation systems and intravesical therapies are emerging as alternatives for patients unresponsive to drugs, driving growth in device-based interventions.
Improved Healthcare Access
Enhanced healthcare infrastructure, availability of specialized urology centers, advanced diagnostics, and supportive reimbursement policies are facilitating faster adoption of OAB therapies, particularly in developed regions.
Lifestyle and Societal Factors
Sedentary habits, stress, and poor dietary patterns are increasingly linked to bladder dysfunction. Growing awareness of lifestyle-related triggers is pushing demand for both preventive measures and therapeutic solutions.
Get a sneak peek at the overactive bladder treatment market dynamics @ Overactive Bladder Treatment Market Trends
Regional Overactive Bladder Treatment Market Insights
North America is expected to capture the largest share of the overactive bladder treatment market, driven by multiple factors. The region's lead is due primarily to the rising number of OAB patients, influenced by an aging population and the growing prevalence of chronic conditions. Additionally, the increasing rates of neurological, urological, bladder, and prostate cancers are boosting demand for effective OAB therapies. Frequent product approvals and the introduction of innovative treatments by prominent industry players further support market growth. Leading companies in the region are investing heavily in R&D to develop advanced OAB solutions. For instance, in June 2025, Neuspera Medical, Inc. announced FDA approval of its integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI), a primary symptom of OAB. Neuspera’s iSNM system offers patients a less invasive alternative compared to traditional sacral neuromodulation therapies.
To know more about why North America is leading the market growth in the overactive bladder treatment market, get a snapshot of the Overactive Bladder Treatment Market Outlook
Recent Developmental Activities in the Overactive Bladder Treatment Market
- In July 2025, Eisai Co., Ltd. launched Beova® Tablets, a once-daily, selective β3-adrenergic receptor agonist designed to relax the bladder muscle, improve urine storage, and alleviate symptoms such as urgency, increased urinary frequency, and urge urinary incontinence.
- In June 2025, Marksans Pharma Ltd. announced that its UK subsidiary, Relonchem Ltd., had obtained marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency for its Oxybutynin hydrochloride oral solution. The approval covers the product at a strength of 2.5 mg per 5 ml.
- In June 2025, Neuspera Medical, Inc. announced that the FDA approved its integrated sacral neuromodulation (iSNM) system for the treatment of urinary urge incontinence (UUI), a key symptom of overactive bladder.
- In April 2025, Amara Therapeutics, a medical technology company based in Ireland specializing in women’s health, revealed the initiation of a clinical trial to assess its digital therapeutic approach for treating overactive bladder in women.
Overactive Bladder Treatment Overview
Overactive bladder (OAB) treatment focuses on reducing the frequency, urgency, and urge incontinence symptoms while improving overall quality of life. First-line approaches typically involve lifestyle and behavioral interventions, such as bladder training, pelvic floor muscle exercises, fluid management, and dietary adjustments to reduce bladder irritants like caffeine and alcohol. These non-pharmacological strategies aim to strengthen bladder control and retrain voiding habits, often providing significant relief with minimal risk.
| Overactive Bladder Treatment Market Report Metrics | Details |
| Coverage | Global |
| Study Period | 2022–2032 |
| Overactive Bladder Treatment Market CAGR | ~4% |
| Overactive Bladder Treatment Market Size by 2032 | USD 5.1 Billion |
| Key Overactive Bladder Treatment Companies | Pfizer Inc., Astellas Pharma Inc., Amneal Pharmaceuticals LLC, Sumitomo Pharma Co., Ltd., Novartis AG, Endo, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Hisamitsu Pharmaceutical Co., Inc., Viatris Inc., Medtronic, Axonics, Inc., Valencia Technologies, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Zydus Group, DAIICHI SANKYO COMPANY, LIMITED, KYORIN Pharmaceutical Co., Ltd., Neuspera Medical, and others |
Overactive Bladder Treatment Market Assessment
-
Overactive Bladder Treatment Market Segmentation
- Overactive Bladder Treatment Market Segmentation By Treatment Type: Neurostimulation Devices, Anticholinergic Drugs, Antispasmodic Drugs, and Others
- Overactive Bladder Treatment Market Segmentation By End-User: Hospitals & Clinics, Academic and Research Institutes, and Others
- Overactive Bladder Treatment Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the overactive bladder treatment market are set to emerge as the trendsetter explore @ Overactive Bladder Treatment Market Analysis
Table of Contents
| 1 | Overactive Bladder Treatment Market Report Introduction |
| 2 | Overactive Bladder Treatment Market Executive Summary |
| 3 | Competitive Landscape |
| 4 | Regulatory Analysis |
| 5 | Overactive Bladder Treatment Market Key Factors Analysis |
| 6 | Overactive Bladder Treatment Market Porter’s Five Forces Analysis |
| 7 | Overactive Bladder Treatment Market Layout |
| 8 | Overactive Bladder Treatment Market Company and Product Profiles |
| 9 | KOL Views |
| 10 | Project Approach |
| 11 | About DelveInsight |
| 12 | Disclaimer & Contact Us |
Interested in knowing the overactive bladder treatment market by 2032? Click to get a snapshot of the Overactive Bladder Treatment Market Assessment
Related Reports
Overactive Bladder Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key overactive bladder companies, including LG Life Sciences, Kyorin Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astellas Pharma Inc., Lee's Pharmaceuticals Limited, R-Pharm, Synergy Research Inc., Imbrium Therapeutics, Purdue Pharma LP, Ono Pharmaceuticals Co. Ltd, Data & Inference Inc., Bayer, Sumitomo Pharma America Inc., Pfizer, among others.
Overactive Bladder Clinical Trial Analysis
Overactive Bladder Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key overactive bladder companies, including Dong-A ST Co., Ltd., AbbVie, Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics, among others.
Bladder Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bladder cancer companies, including Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International, Johnson & Johnson, Merck & Co., Inc., Vault Pharma Inc., Vyriad Inc., among others.
Neurostimulation Devices Market
Neurostimulation Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key neurostimulation devices companies, including Abbott Laboratories, Smith’s Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic plc., Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., among others.
Implantable Neurostimulation Devices Market
Implantable Neurostimulation Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key implantable neurostimulation devices companies, including Medtronic, Boston Scientific Corporation, Abbott Laboratories, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
